[go: up one dir, main page]

WO1999000150A3 - Ciblage d'un medicament radiopharmaceutique peptidique utilisant in vivo la barriere hemato-encephalique d'un primate et un anticorps monoclonal dirige contre le recepteur humain de l'insuline - Google Patents

Ciblage d'un medicament radiopharmaceutique peptidique utilisant in vivo la barriere hemato-encephalique d'un primate et un anticorps monoclonal dirige contre le recepteur humain de l'insuline Download PDF

Info

Publication number
WO1999000150A3
WO1999000150A3 PCT/US1998/013398 US9813398W WO9900150A3 WO 1999000150 A3 WO1999000150 A3 WO 1999000150A3 US 9813398 W US9813398 W US 9813398W WO 9900150 A3 WO9900150 A3 WO 9900150A3
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibody
human insulin
insulin receptor
brain barrier
vivo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/013398
Other languages
English (en)
Other versions
WO1999000150A9 (fr
WO1999000150A2 (fr
Inventor
William M Pardridge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Priority to AU82698/98A priority Critical patent/AU8269898A/en
Publication of WO1999000150A2 publication Critical patent/WO1999000150A2/fr
Publication of WO1999000150A3 publication Critical patent/WO1999000150A3/fr
Publication of WO1999000150A9 publication Critical patent/WO1999000150A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Selon cette invention, le peptide [125I]-Aβ1-40 a été mono-biotinylé et conjugué à un système de ciblage cérébral et d'administration d'un médicament à la barrière hémato-encéphalique (BBB), système renfermant un complexe de l'anticorps monoclonal 83-14 (MAb) dirigé contre le récepteur humain de l'insuline et marqué par la streptavidine (SA) et ce, dans le but de produire, trois heures après l'injection intraveineuse, un accroissement sensible de l'assimilation du [125I]-bio-Aβ1-40 par le cerveau du singe rhésus, par rapport à l'assimilation obtenue sans administration de médicament à la BBB.
PCT/US1998/013398 1997-06-27 1998-06-26 Ciblage d'un medicament radiopharmaceutique peptidique utilisant in vivo la barriere hemato-encephalique d'un primate et un anticorps monoclonal dirige contre le recepteur humain de l'insuline Ceased WO1999000150A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU82698/98A AU8269898A (en) 1997-06-27 1998-06-26 Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5106597P 1997-06-27 1997-06-27
US60/051,065 1997-06-27

Publications (3)

Publication Number Publication Date
WO1999000150A2 WO1999000150A2 (fr) 1999-01-07
WO1999000150A3 true WO1999000150A3 (fr) 1999-04-01
WO1999000150A9 WO1999000150A9 (fr) 1999-05-14

Family

ID=21969115

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/013398 Ceased WO1999000150A2 (fr) 1997-06-27 1998-06-26 Ciblage d'un medicament radiopharmaceutique peptidique utilisant in vivo la barriere hemato-encephalique d'un primate et un anticorps monoclonal dirige contre le recepteur humain de l'insuline

Country Status (2)

Country Link
AU (1) AU8269898A (fr)
WO (1) WO1999000150A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486399B2 (en) 2011-12-02 2013-07-16 Armagen Technologies, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
US8497246B2 (en) 2006-08-18 2013-07-30 Armagen Technologies, Inc. Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8834874B2 (en) 2009-10-09 2014-09-16 Armagen Technologies, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the CNS
US8974791B2 (en) 2007-07-27 2015-03-10 Armagen Technologies, Inc. Methods and compositions for increasing α-L-iduronidase activity in the CNS
US9533055B2 (en) 2009-03-18 2017-01-03 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of IgG-decoy receptor fusion proteins
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
CA2393292A1 (fr) * 1999-12-13 2001-06-21 Cambridge Antibody Technology Limited Elements de liaison specifiques du cerveau
JP5153986B2 (ja) * 2000-09-06 2013-02-27 アベンティス・ファーマ・ソシエテ・アノニム アミロイドーシスと関連する疾患のための方法及び組成物
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
KR20040029968A (ko) * 2001-05-04 2004-04-08 니목스 코포레이션 신경 사 단백질에 대한 항체를 사용하여 세포 사멸을억제하는 방법
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7399613B2 (en) 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7226903B2 (en) 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
EP2292273A3 (fr) 2001-10-10 2011-11-23 BioGeneriX AG Remodelage et Glycoconjugaison de Peptides
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US7297511B2 (en) 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
EP1608688B1 (fr) 2003-03-14 2013-02-27 BioGeneriX AG Polymeres hydrosolubles ramifies et conjugues de ceux-ci
MXPA05010773A (es) 2003-04-09 2005-12-12 Neose Technologies Inc Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
WO2004091499A2 (fr) 2003-04-09 2004-10-28 Neose Technologies, Inc. Formation intracellulaire de conjugues de peptides
CA2524936A1 (fr) 2003-05-09 2004-12-02 Neose Technologies, Inc. Compositions et procedes pour preparer des mutants de glycosylation de l'hormone de croissance humaine
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
WO2005012484A2 (fr) 2003-07-25 2005-02-10 Neose Technologies, Inc. Conjugues anticorps-toxines
MXPA06005732A (es) 2003-11-24 2006-08-17 Neose Technologies Inc Eritropoyetina glucopegilada.
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
BRPI0506741A (pt) 2004-01-08 2007-05-15 Neose Technologies Inc glicosilação de peptìdeos ligados a o
WO2005111225A1 (fr) 2004-05-04 2005-11-24 Novo Nordisk Health Care Ag Glycoformes de polypeptides o-liees et leur procede de fabrication
WO2006010143A2 (fr) 2004-07-13 2006-01-26 Neose Technologies, Inc. Remodelage de peg ramifie et glycosylation de peptide-1 semblable a glucagon [glp-1]
WO2006031811A2 (fr) 2004-09-10 2006-03-23 Neose Technologies, Inc. Interferon alpha glycopegyle
CA2585758C (fr) 2004-10-29 2017-08-01 Neose Technologies, Inc. Remodelage et glycopegylation du facteur de croissance des fibroblastes (fgf)
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
EP1838854B1 (fr) 2004-12-15 2012-10-31 Janssen Alzheimer Immunotherapy Anticorps reconnaissant le peptide beta amyloide
MX2007008229A (es) 2005-01-10 2007-09-11 Neose Technologies Inc Factor estimulador de colonias de granulocitos glicopegilado.
EP1871795A4 (fr) 2005-04-08 2010-03-31 Biogenerix Ag Compositions et méthodes utilisées pour la préparation de mutants par glycosylation de l'hormone de croissance humaine résistant à la protéase
WO2006127910A2 (fr) 2005-05-25 2006-11-30 Neose Technologies, Inc. Formulations d'erythropoietine glycopegylees
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
EP2049144B8 (fr) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation de peptides par l'intermédiaire de séquences de glycosylation à liaison o
EP2054521A4 (fr) 2006-10-03 2012-12-19 Novo Nordisk As Méthodes de purification de conjugués de polypeptides
KR20100016160A (ko) 2007-04-03 2010-02-12 바이오제너릭스 에이지 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP2170919B8 (fr) 2007-06-12 2016-01-20 ratiopharm GmbH Procédé amélioré pour la production de sucres de nucléotide
EP2182983B1 (fr) 2007-07-27 2014-05-21 Janssen Alzheimer Immunotherapy Traitement de maladies amyloïdogéniques avec anti-abeta anticorps humanise
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2257311B1 (fr) 2008-02-27 2014-04-16 Novo Nordisk A/S Molécules de facteur viii conjuguées
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2488210A4 (fr) 2009-10-12 2014-04-30 Smith Holdings Llc Procédés et compositions de modulation de l'expression génique en utilisant des médicaments à base d'oligonucléotides administrés in vivo ou in vitro
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
PL3583120T3 (pl) 2017-02-17 2023-01-09 Denali Therapeutics Inc. Konstruowane polipeptydy wiążące receptory transferyny
US10143187B2 (en) 2017-02-17 2018-12-04 Denali Therapeutics Inc. Transferrin receptor transgenic models

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000834A1 (fr) * 1986-07-30 1988-02-11 The Regents Of The University Of California Peptides chimeriques pour l'apport de neuropeptides au travers de la barriere hemato-encephalique
WO1994002178A1 (fr) * 1992-07-27 1994-02-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Ciblage de liposomes sur la barriere hemato-encephalique
EP0599303A2 (fr) * 1992-11-27 1994-06-01 Takeda Chemical Industries, Ltd. Conjugués peptidiques

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000834A1 (fr) * 1986-07-30 1988-02-11 The Regents Of The University Of California Peptides chimeriques pour l'apport de neuropeptides au travers de la barriere hemato-encephalique
WO1994002178A1 (fr) * 1992-07-27 1994-02-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Ciblage de liposomes sur la barriere hemato-encephalique
EP0599303A2 (fr) * 1992-11-27 1994-06-01 Takeda Chemical Industries, Ltd. Conjugués peptidiques

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
B.V.ZLOKOVIC ET AL.: "Brain uptake of circulating apolipoproteins J and E complexedto Alzheimer's amyloid ß", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS., vol. 205, no. 2, 15 December 1994 (1994-12-15), ORLANDO, US, pages 1431 - 1437, XP002090773 *
MARTEL, C. L. ET AL: "Transport of apolipoproteins E and J at the blood - brain barrier. Relevance to Alzheimer's disease", S.T.P. PHARMA SCI., VOL. 7, NO. 1, PAGE(S) 28-36, January 1997 (1997-01-01) - February 1997 (1997-02-01), XP002090769 *
MARTEL, CYNTHIA L. ET AL: "Blood - brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer's amyloid ß in guinea pigs", NEUROSCI. LETT., VOL. 206, NO. 2,3, PAGE(S) 157-60, 1996, XP002090771 *
PARDRIDGE, WILLIAM M. ET AL: "Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood - brain barrier in vivo in the primate.", PHARMACEUTICAL RESEARCH, 1995, VOL. 12, NO. 6, PAGES 807-816., XP002090768 *
PODUSLO, JOSEPH F. ET AL: "Permeability and residual plasma volume of human, Dutch variant, and rat amyloid ß-protein 1-40 at the blood - brain barrier", NEUROBIOL. DIS., 1997, VOL. 4, NO. 1, PAGE(S) 27-34, XP002090770 *
SAITO Y ET AL: "Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex.", PROC NATL ACAD SCI U S A, OCT 24 1995, VOL. 92, NO. 22, PAGE(S) 10227-31, XP002090767 *
WU, DAFANG ET AL: "Drug targeting of a peptide radiopharmaceutical through the primate blood - brain barrier in vivo with a monoclonal antibody to the human insulin receptor", J. CLIN. INVEST., VOL. 100, NO. 7, PAGE(S) 1804-1812, 1 October 1997 (1997-10-01), XP002090766 *
ZLOKOVIC B V ET AL: "Glycoprotein 330-megalin: Probable role in receptor -mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood - brain and blood-cerebrospinal fluid barriers.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, VOL. 93, NO. 9, 1996, PAGE(S) 4229-4234., XP002090772 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8759297B2 (en) 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
US8497246B2 (en) 2006-08-18 2013-07-30 Armagen Technologies, Inc. Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
US10144783B2 (en) 2006-08-18 2018-12-04 Armagen, Inc. Macromolecular compositions that cross the blood-brain barrier and methods of use thereof
US8753610B2 (en) 2006-08-18 2014-06-17 Armagen Technologies, Inc. Methods for diagnosing CNS disorders with fusion antibodies that cross the blood-brain barrier in both directions
US8974791B2 (en) 2007-07-27 2015-03-10 Armagen Technologies, Inc. Methods and compositions for increasing α-L-iduronidase activity in the CNS
US9567400B2 (en) 2007-07-27 2017-02-14 Armagen Technologies, Inc. Methods and compositions for increasing α-L-iduronidase activity in the CNS
US11512145B2 (en) 2007-07-27 2022-11-29 Armagen, Inc. Methods and compositions for increasing alpha-L-iduronidase activity in the CNS
US10202467B2 (en) 2007-07-27 2019-02-12 Armagen, Inc. Methods and compositions for increasing α-L-iduronidase activity in the CNS
US9533055B2 (en) 2009-03-18 2017-01-03 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of IgG-decoy receptor fusion proteins
US10011651B2 (en) 2009-10-09 2018-07-03 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the CNS
US8834874B2 (en) 2009-10-09 2014-09-16 Armagen Technologies, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the CNS
US11028156B2 (en) 2009-10-09 2021-06-08 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the CNS
US12043661B2 (en) 2009-10-09 2024-07-23 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the CNS
US9975955B2 (en) 2011-12-02 2018-05-22 Armagen, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
US8715661B2 (en) 2011-12-02 2014-05-06 Armagen Technologies, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
US8486399B2 (en) 2011-12-02 2013-07-16 Armagen Technologies, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
US8920801B2 (en) 2011-12-02 2014-12-30 Armagen Technologies, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU

Also Published As

Publication number Publication date
WO1999000150A9 (fr) 1999-05-14
WO1999000150A2 (fr) 1999-01-07
AU8269898A (en) 1999-01-19

Similar Documents

Publication Publication Date Title
WO1999000150A3 (fr) Ciblage d'un medicament radiopharmaceutique peptidique utilisant in vivo la barriere hemato-encephalique d'un primate et un anticorps monoclonal dirige contre le recepteur humain de l'insuline
NO20015584D0 (no) Lantidsvarende insulintrofiske peptider
EP1097727A3 (fr) Cartouche de médicament pour injecteur sans aiguille et adaptateur de remplissage
CA2066244A1 (fr) Conjugues d'un agent neuropharmaceutique - anticorps specifique d'un recepteur de la transferrine
PE20071063A1 (es) Formulaciones de proteinas estables
ES2109891A1 (es) Jeringa desechable con dos camaras de volumen variable.
WO2000069900A3 (fr) Protection de peptides therapeutiques endogenes contre l'activite peptidase par conjugaison de composants sanguins
FR2736553B1 (fr) Seringue d'injection, notamment de produits medicaux liquides, a protecteur d'aiguille mobile
IL136512A0 (en) Intravenous infusion administration set
AU6135399A (en) Intravenous infusion needle with soft body
FR2748588B1 (fr) Dispositif comportant au moins un reseau de neurones pour determiner la quantite d'une substance a administrer a un patient, notamment de l'insuline
CA2064689A1 (fr) Conjugues de proteines ou de peptides stabilises
WO1999024074A3 (fr) Nouveaux conjugues opioides et supports endogenes
WO2002036073A3 (fr) Conjugues antagoniste du recepteur-lipide et vehicules d'apport contenant lesdits conjugues
WO2003037272A3 (fr) Conjugues de polymeres/peptides thymosine alpha 1
WO2003009870A1 (fr) Remedes traitant le cancer du sein
ID23424A (id) Glikokonjugat dari 20(s)-kamptotesin
JP2002530353A5 (fr)
WO2000070665A3 (fr) Peptides antiangiogeniques durables
IL161665A0 (en) Method of administering a thymosin alpha 1 peptide
WO2002085418A3 (fr) Derives d'octreotide glycosyles radioactifs a marquage tc et re
EA200200234A1 (ru) Препараты для парентерального применения эстрамустин фосфата и альбумина
WO2001082795A3 (fr) Agents d'imagerie par resonance magnetique utilises pour apporter des agents therapeutiques
AU2001264339A1 (en) An-egg protein anti-cancer injection drug and a procedure to obtain such a drug
WO2002002150A3 (fr) Conjugats stables d'iode radioactif et procédés de synthese

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/9-9/9, DRAWINGS, REPLACED BY NEW PAGES 1/11-11/11; DUE TO LATE TRANSMITTAL BY THE RECEIVINGOFFICE

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1999505819

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA